Analysis of Unity Biotechnology, Inc. (0YC0)
Unity Biotechnology, Inc. is a biotechnology company that focuses on developing therapeutics to extend healthspan by slowing, halting, or reversing diseases of aging. The company is currently working on developing drugs that target senescent cells, which are cells that have stopped dividing and accumulate with age, contributing to various age-related diseases.
Looking at the financial data, the stock price of Unity Biotechnology, Inc. has been fluctuating recently. The Relative Strength Index (RSI) values indicate that the stock is not currently overbought or oversold, hovering around the mid-range. The Moving Average Convergence Divergence (MACD) indicator shows a slightly negative trend, but the MACD histogram suggests some positive momentum.
Overall, Unity Biotechnology, Inc. seems to be in a phase of consolidation, with no clear trend in the short term. Investors may want to keep an eye on upcoming developments in the company's drug pipeline and clinical trials to assess its future growth potential.
Balance Sheet
These are balance sheets. Here are the conclusions:
1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, peaking at $234,386,000,000 in 2018.
4. Total liabilities have also been on the rise, with the highest value in 2018 at $255,355,000,000.
5. Shareholders' equity has generally increased, with the highest value in 2018 at $107,147,000,000.
6. The company has been investing more in non-current assets over the years.
7. There is a fluctuation in current assets, possibly due to changes in short-term investments and receivables.
8. The company has been relying more on long-term debt to finance its operations.
9. Retained earnings have been positive, indicating profitability and reinvestment in the business.
10. Overall, the company's financial position seems stable and has been growing steadily over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:
1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show a pattern of common stock repurchase and issuance, as well as long-term debt issuance and payments.
5. Investing activities include acquisitions, capital expenditures, and the sale and purchase of investments.
6. The end cash position has also been fluctuating, reaching its highest value in 2020 and its lowest in 2022.
These conclusions provide insights into the company's financial performance and management of cash flows over the years.
Earnings estimate
Based on analysts' estimates for future quarterly and annual earnings per share:
1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.33, compared to $1.26 a year ago. The range of estimates is between $1.27 and $1.36, based on 26 analysts' forecasts.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.53, compared to $1.46 a year ago. The range of estimates is between $1.44 and $1.63, based on 25 analysts' forecasts.
3. For the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.59, compared to $6.13 a year ago. The range of estimates is between $6.43 and $6.92, based on 39 analysts' forecasts.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $7.23, compared to $6.59 a year ago. The range of estimates is between $6.40 and $7.90, based on 39 analysts' forecasts.
Overall, it appears that analysts are generally forecasting an increase in earnings per share for both the upcoming quarters and the next fiscal years compared to the previous periods.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:
1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:
1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. The company is projected to experience steady growth in the upcoming quarters and years, indicating a positive outlook for its performance.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released After Hours. The results from October 31, 2024, were not provided at the time. The results from August 1, 2024, showed an EPS estimate of 1.33.
Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company. Here is a summary of the key information:
1. Financials:
- Cash Flow: Operating cash flow (TTM) is $110,563,000,320 and levered free cash flow (TTM) is $84,726,874,112.
- Balance Sheet: Total cash (MRQ) is $67,150,000,128, total debt (MRQ) is $104,590,000,128, current ratio (MRQ) is 1.037, book value per share (MRQ) is $4.837, total cash per share (MRQ) is $4.379, and total debt to equity ratio (MRQ) is 140.968.
- Profit Margin: 26.306%
- Fiscal Year Ends: September 30, 2023
- Income Statement: EBITDA is $131,393,000,000, revenue (TTM) is $381,623,009,280, diluted EPS (TTM) is $6.44, gross profit (TTM) is $169,148,000,000, revenue per share (TTM) is $24.537, net income to common (TTM) is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth YoY is -2.2%.
- Operating Margin: 30.743%
- Return on Assets (TTM): 22.073%
- Return on Equity (TTM): 147.25%
2. Stock Statistics:
- Short Ratio: 1.66
- Float Shares: 15,308,320,742
- Shares Short: 94,308,265
- Average 10-Day Volume: 52,903,608
- Average 90-Day Volume: 62,823,269
- Shares Outstanding: 15,334,099,968
- Percent Held by Insiders: 5.22%
- Percent Held by Institutions: 57.555%
- Short Percent of Shares Outstanding: 0.62%
3. Valuation Metrics:
- PEG Ratio: 26.213
- Forward P/E: 26.213
- Trailing P/E: 29.429
- Enterprise Value: $2,948,462,018,560
- Price to Book (MRQ): 39.181
- Price to Sales (TTM): 7.615
- Enterprise to EBITDA: 22.745
- Enterprise to Revenue: 7.726
- Market Capitalization: $2,906,118,684,672
4. Stock Price Summary:
- Beta: 1.264
- 50-Day Moving Average: $173.6936
- 200-Day Moving Average: $180.7906
- 52-Week Low: $164.08
- 52-Week High: $199.62
- 52-Week Change: 8.253%
5. Dividends and Splits:
- Payout Ratio: 14.93%
- Dividend Date: May 16, 2024
- Last Split Date: August 31, 2020
- Ex-Dividend Date: May 10, 2024
- Last Split Factor: 4-for-1 split
- Forward Annual Dividend Rate: $1
- 5-Year Average Dividend Yield: 0.73%
- Forward Annual Dividend Yield: 0.53%
- Trailing Annual Dividend Rate: $0.97
- Trailing Annual Dividend Yield: 0.51%
Income statement 💸
These are the revenue figures. Here are the conclusions:
1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been relatively stable, with gross profit ranging from around $105 billion to $169 billion.
3. Operating income has also shown a consistent growth trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has increased from $57.4 billion in 2020 to $97 billion in 2023, indicating improving profitability.
5. Earnings per share (EPS) have also shown an upward trend, with both basic and diluted EPS increasing over the years.
6. The company has been able to manage its operating expenses effectively, as seen in the growth of operating income outpacing the increase in operating expenses.
7. The effective tax rate has remained relatively stable over the years, indicating consistent tax management strategies.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.MACD of 0YC0